Clinical Study
Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
Table 1
Baseline demographics of the study participants.
| | Demographics () |
| | Gender (% male) | 77 | | Race (% Caucasian) | 86 | | Average age at transplant (years) | | | BMI at transplant (kg/m2)# | | | BMI at NODAT diagnosis (kg/m2) | | | Average time to NODAT diagnosis (mo.) | | | Donor type (% of patients) | | | Deceased | 50 | | Living, genetically related | 32 | | Living, genetically unrelated | 18 | | Immunosuppressants (number of patients/(%)) | | | Tacrolimus | 19 (86) | | Sirolimus | 9 (41) | | Mycophenolate mofetil | 8 (36) | | Cyclosporine | 2 (9) | | Mycophenolic acid | 1 (4.5) | | Azathioprine | 1 (4.5) |
|
|
Values are mean SD.
Data available on 19 of 22 patients.
|
